Drug intelligence / Profile preview

NH300231

Development stage: Unknown
Lead developer: Jiangsu Nhwa Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

NH300231 is an investigational small molecule atypical antipsychotic being developed by Jiangsu Enhua Pharmaceutical for the treatment of schizophrenia. It functions as a multi-target antagonist, primarily focusing on the Dopamine D2 and Serotonin 5-HT2A receptors. This pharmacological profile is intended to address the positive symptoms of schizophrenia through D2 blockade while mitigating negative symptoms and cognitive deficits through 5-HT2A antagonism, potentially offering a better safety profile regarding extrapyramidal side effects compared to first-generation antipsychotics. The drug is currently in early-stage clinical development in China.

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on NH300231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NH300231.

Explore the full profile